)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
BONESUPPORT
BONESUPPORT (BONEX) investor relations material
BONESUPPORT Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary22 Oct, 2026
Executive summary
Q3 net sales rose 39% reported and 38% at constant exchange rates to SEK 408.8m; adjusted operating result was SEK 139.3m and adjusted operating margin was 34%.
Growth across the US and EUROW coincided with CMS reimbursement changes and publication of SOLARIO results.
Financial highlights
Net sales were SEK 408.8m versus SEK 294.1m in Q3 2025; reported growth was 39% and CER growth was 38%.
Reported operating profit was SEK 123.4m versus SEK 65.4m; adjusted operating result was SEK 139.3m versus SEK 78.6m.
Operating cash flow was SEK 137.8m, with 99% cash conversion; quarter-end cash was SEK 510.5m.
Q3 gross profit was SEK 376.0m; net income was SEK 92.4m and diluted EPS was SEK 1.39.
9M net sales were SEK 1,088.6m, up 33% CER; adjusted operating result was SEK 328.3m.
Outlook and guidance
FY 2026 sales-growth guidance remained 33%–36% at constant exchange rates.
Higher CMS reimbursement for qualifying CERAMENT G cases took effect October 1, 2026, and is expected to support broader use.
The complete CERAMENT V supplemental data package was submitted to the FDA in September; review continued, with a formal response expected in Q4 or Q1.
Spine market-entry plans remained on track, with CERAMENT BVF in the short term and antibiotic-eluting CERAMENT longer term.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from BONESUPPORT
- Q2 net sales up 25% (30% CER), 29% margin, strong cash, and upgraded full-year guidance.BONEX
Q2 2026 - Segment-focused strategy, 460,000 U.S. procedures, and new clinical studies drive growth.BONEXCMD 2026
- Strong sales growth, high margins, and robust US performance drive positive outlook.BONEXQ1 2026
- Q4 sales up 22% (36% CER), 26% margin, strong US growth, 2026 sales to rise 35%+ CER.BONEXQ4 2025
- Q3 sales up 24%, US segment leads, gross margin 92.9%, strong cash flow and new clinical milestones.BONEXQ3 2025
- Q3 sales up 50% with record US growth; SOLARIO study supports new infection treatment standard.BONEXQ3 2024
- Q2 sales up 57% year-over-year, with strong North America growth and raised 2024 outlook.BONEXQ2 2024
- Q1 2025 net sales up 54% with record CERAMENT G growth and strong cash flow.BONEXQ1 2025
- Q4 sales up 49% with record cash flow and strong 2025 growth outlook driven by CERAMENT G.BONEXQ4 2024
Next BONESUPPORT earnings date
Q4 202623 Feb, 2027
BONESUPPORT
Next BONESUPPORT earnings date
Q4 202623 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
BONESUPPORT HOLDING, an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company's product, CERAMENT is a medical device that helps stimulate and accelerate the patient's own bone healing process. It is also involved in designing, developing, manufacturing, selling, marketing, and distributing of therapeutic products; and provision of research activities for new applications for drugs